Skip Navigation



Japanese Journal of Clinical Oncology Advance Access published online on October 10, 2009
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyp127
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Onda, T.
Right arrow Articles by Taketani, Y.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Onda, T.
Right arrow Articles by Taketani, Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2009). Published by Oxford University Press. All rights reserved

The Optimal Debulking after Neoadjuvant Chemotherapy in Ovarian Cancer: Proposal based on Interval Look During Upfront Surgery Setting Treatment

Takashi Onda1,2, Hiroyuki Yoshikawa1,3, Toshiharu Yasugi1,4, Koji Matsumoto1,3 and Yuji Taketani1

1 Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo
2 Division of Gynecologic Oncology, National Cancer Center Hospital, Tokyo
3 Department of Obstetrics and Gynecology, University of Tsukuba, Ibaraki
4 Department of Gynecology, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan

For reprints and all correspondence: Takashi Onda, Division of Gynecologic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. E-mail: taonda{at}ncc.go.jp

Received May 29, 2009; accepted August 29, 2009

Objective: The optimal goal of interval debulking surgery (IDS) following neoadjuvant chemotherapy (NAC) remains undefined. The aim of this study was to determine the optimal goal of IDS following NAC on the basis of long-term survival by the disease status at the end of interval look surgery (ILS) or IDS during the treatment in the setting of upfront primary debulking surgery (PDS).

Methods: From January 1986 through December 2000, we performed treatment in the setting of upfront PDS in 128 patients with Stage III/IV epithelial ovarian cancer. Sixty-six patients with residual disease (RD) at PDS underwent interval surgery (IS) such as ILS or IDS; 4 patients after two cycles of chemotherapy and 62 after three or more cycles. We investigated how disease status at the end of IS was associated with overall survival (OS).

Results: The 5-year OS rates for no, minimal and gross RD were not available (n = 0), 67% (n = 3) and 0% (n = 1) after two cycles, and 47% (n = 42), 0% (n = 18) and 0% (n = 2) after three or more cycles, respectively. No visible tumors at the end of IS after three or more cycles of chemotherapy were necessary for 5-year survival.

Conclusions: If the optimal goal of IDS is defined as the surgery that is expected to result in long-term survival in the NAC setting treatment, our data on the assessment of peritoneal findings during the upfront PDS setting treatment suggest that only complete resection with no RD could be the optimal goal of IDS in the NAC setting treatment.

Key Words: ovarian cancer • neoadjuvant therapy • gynecol-surg • chemo-gynecology


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.